Pfizer's LYRICA Meets Primary Endpoint in Phase III Trial in Pediatric Epilepsy

Pfizer Inc. (NYSE: PFE) announced on 5/17/18 positive top-line results of a Phase 3 study examining the use of Lyrica (pregabalin) Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age. Results showed that adjunctive treatment with Lyrica 14 mg/kg/day resulted in a statistically significant reduction in seizure frequency versus placebo, the primary efficacy endpoint.